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OBJECTIVE 
 
 
 
 
1. To study the recurrence pattern and disease-free survival of 
patients undergoing radical cystectomy for bladder cancer 
2. To study the effect of lymphadenectomy on recurrence in bladder 
cancer after radical cystectomy 
3. To study the prognostic factors governing disease-free survival 
after radical cystectomy 
4. To do a descriptive analysis of patients undergoing radical 
cystectomy, to study the morbidity pattern and the quality of life 
after surgery 
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MATERIALS AND METHODOLOGY 
 
 
 
 
 From January 2001 to March 2007, 37 patients underwent radical 
cystectomy for bladder cancer. These patients were followed up till 
October 2007. The recurrence pattern and the time to recurrence were 
studied at follow up. Prognostic factors such as histology, age, grade and 
stage of the disease that influence the survival and recurrence were 
studied. The extent of lymphadenectomy and pathological nodal status 
were correlated with the recurrence. The analysis was done using the 
SPSS 11.0.1 (15 Nov 2001) statistical package. 
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REVIEW OF LITERATURE 
 
 
 
 
EPIDEMIOLOGY 
 
 
 Fifty-four thousand new cases of bladder cancer are diagnosed 
each year. It is the second most common genitourinary cancer and results 
in over 12,000 cancer-related deaths annually. Twenty percent to 25% of 
newly diagnosed bladder cancer consist of muscle-invasive disease, with 
majority of these invasive bladder cancers demonstrating invasion at the 
time of diagnosis. While tumor grade and stage do influence progression, 
only approximately 15% of superficial tumors will eventually develop 
the characteristic features of muscle-invasion. For those that become 
muscle-invasive, however, the risk of metastasis and mortality 
unquestionably and dramatically rises. 
 
 More than 90% of invasive and noninvasive bladder tumors are 
transitional cell carcinomas (TCCs). Invasive bladder cancer can 
however be of squamous cell carcinoma(3%), adenocarcinoma(2%), or 
small cell carcinoma(<1%) origin. TCCs may also contain focal areas of  
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squamous or glandular differentiation. These have been traditionally 
classified and managed as TCC, but future investigation may 
demonstrate that these historical variants are in fact associated with 
different outcomes and should be treated as different pathologic entities. 
 Bladder cancer is 2.5 times more common in men than in women. 
Bladder cancer has rarely been found incidentally at autopsy. Bladder 
cancer incidence increases with age in both sexes. Males have a higher 
5-year survival rates than women. Survival by stage at presentation is 
more favorable for whites. Although the vast majority of bladder cancers 
in both sexes and races are TCCs, a higher proportion of bladder cancers 
other than TCCs occur in African Americans and in females, and the 
relative poor outcomes from these tumors may explain some of the racial 
and sex differences in bladder cancer mortality as well. 
 
 The crude incidence rate of bladder cancer in males according to 
the Madras Metropolitan Tumor Registry is 2.1/100,000 population, and 
in females it is 0.8/100,000. In India, the crude incidence rate of bladder 
cancer in males and females is 2.4 and 0.7/100,000 population 
respectively. In the world, the crude incidence rate of bladder cancer in 
males and females is 25.4 and 8.54/100,000 population respectively. 
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Since the 1950s, the incidence of bladder cancer has risen by 
approximately 50%. In comparison, there has been a decrease in bladder 
cancer’s mortality rate during the same interval by approximately 33%. 
The reduction in mortality has been primarily achieved in men. The 
median age at diagnosis for TCC in men is 69 years and in females is 71 
yrs. Younger patients appear to have a more favorable prognosis because 
they present more frequently with superficial, low-grade tumors; 
however, the risk for disease progression is the same, grade-for-grade, in 
younger patients as in older ones. 
 
 
ETIOLOGY 
 
 
 Factors reported to be causally related to bladder cancer’s 
development and progression include occupational exposure to 
chemicals; cigarette smoking; coffee drinking; ingestion of analgesics or 
artificial sweeteners; bacterial, parasitic, fungal, and viral infections; 
harboring of bladder calculi, and receiving genotoxic chemotherapeutic 
agents. Carcinogen produce lesions in the DNA of target cells, both 
initiating and propagating the process of tumorigenesis. It is likely that 
multiple lesions are required to cause malignant transformation of cells. 
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 Oncogenes that have been associated with bladder cancer include 
those of the ras gene family, including the p21 ras oncogene, which in 
some studies, has been found to correlate with higher histologic grade. 
This is a GTPase, transducing signals from the cell membrane to the 
nucleus, affecting proliferation and differentiation. 
 
 Several tumor suppressor gene loci have been closely associated 
with bladder cancer. These include that of the p53 gene on chromosome 
17p; retinoblastoma (Rb) gene on chromosome 13q; genes on 
chromosome 9p in the region 9p21 where the genes for the p19 and p16 
chromosomes reside. Impaired p53 function contributes to an aggressive 
phenotype and paradoxically enhances sensitivity to some 
chemotherapeutic agents. Reduced or abnormal expression/function of 
the products of the genes coding for p15, p16, p21, p27, or pRb would be 
expected to result in uninhibited proliferation and perhaps malignant 
transformation and tumor progression. 
 
 Abnormal expression of the receptor for Epidermal growth factor 
(EGF) occurs in bladder cells and that increased expression is associated 
with more aggressive biologic behaviour. EGF receptor signaling 
induces not only growth, but also cancer cell motility. 
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 Chemicals that have been shown to be carcinogens for bladder 
cancer include aniline dyes, 2-naphtylamine, 4-aminobiphenyl, 
benzidine, 4-nitrobiphenyl and 2-amino-1-naphthol. Most bladder 
carcinogens are aromatic amines. Occupational exposure accounts for 
20% of bladder cancer cases, with long latency periods (30-50 years). 
This is probably related to cumulative dose. 
 
 Cigarette smokers have up to four-fold higher incidence of bladder 
cancer than do people who have never smoked. The risk correlates with 
the number of cigarettes smoked, the duration of smoking, and the 
degree of inhalation of smoke. The risk is observed in both the sexes. 
The reduction of this risk down to baseline takes nearly 20 years after 
cessation. The failure to quit smoking once a diagnosis is made predicts 
a more ominous outcome. 
 
 Consumption of large quantities of analgesic combinations 
containing phenacetin is associated with increased risk of transitional 
cell carcinoma of the renal pelvis and bladder. 
 
 Chronic cystitis in the presence of indwelling catheters or calculi 
is associated with increased risk of squamous cell carcinoma of the 
bladder. Two to 10% of paraplegics with long-term indwelling catheters 
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develop bladder cancer, 80% of which are squamous carcinomas. There 
is also an increased incidence of transitional cell carcinomas in males 
with Schistosoma haematobium cystitis. 
 
 Ectopia vesicae is associated with increased risk of bladder cancer. 
They develop adenocarcinoma of the bladder. 
 
 Patients treated with radiotherapy for carcinoma of uterine cervix 
or rectum have a 2-4 fold increase in risk of developing bladder cancer 
subsequently. The incidence increases if chemotherapy was also 
administered (with or without cyclophosphamide) or even if 
chemotherapy was used alone. The risks of all groups continue to rise 
after 10 years. These tumors are usually of high grade and locally 
advanced at the time of diagnosis. 
DIAGNOSIS 
 
 
 All patients suspected of having bladder cancer should have 
careful cystoscopy. Cystoscopic examination is required to confirm the 
presence of malignancy, characterize its architecture, determine the 
multiplicity of disease, and determine whether there is diffuse mucosal 
involvement. Abnormal areas should be biopsied. Random biopsy of 
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endoscopically normal areas of urothelium are no longer taken routinely 
as part of the standard diagnostic approach in the evaluation of a bladder 
cancer diasthesis when a preliminary cytology has been negative. 
 
 Malignant urothelial cells can be observed on microscopic 
examination of the urinary sediment or bladder washings. 
Characteristically, tumor cells have large nuclei with irregular, coarsely 
textured chromatin. Microscopic cytology is more sensitive in patients 
with high-grade tumors or carcinoma-in-situ. False positive cytology 
may occur in 1-12% cases due to urothelial atypia, inflammation, or 
changes caused by radiation or chemotherapy. It has been estimated that 
the sensitivity of a single barbotage specimen is equivalent to tthat of 
three voided specimens. 
 
PATHOLOGY 
 
Normal Bladder Urothelium 
 
 
 The urothelium of the normal bladder is 3-7 layers thick. There is 
a basal cell layer on which rests one  or more layers of intermediate cells. 
The most superficial layer is composed of large, flat, umbrella cells. The 
urothelium rests on the lamina propria basement membrane. 
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CARCINOMA IN SITU 
 
 
 Carcinoma in situ may appear as a velvety patch of erythematous 
mucosa, although quite often it is endoscopically invisible. 
Histologically, it consists of poorly differentiated transitional cell 
carcinoma confined to the urothelium. Urine cytology is positive in 80-
90% of patients with carcinoma in situ. About 20% of patients treated 
with cystectomy for diffuse carcinoma in situ are found to have 
microscopic muscle invasive carcinoma. 
 
 
TRANSITIONAL CELL CARCINOMA 
 
 
 More than 90% of bladder cancers are transitional cell carcinomas. 
WHO and the ISUP prefer the term Urothelial cancers. They  manifest in 
a variety of patterns of tumor growth including papillary, sessile, 
infiltrating, nodular, mixed, and flat intraepithelial growth. 
Histologically, there are increased number of epithelial cell layers with 
papillary foldings of the mucosa, loss of cell polarity, abnormal cell 
maturation from basal to superficial layers, increased nuclear-
cytoplasmic ratio and increased number of mitosis. Approximately, 70% 
of bladder tumors are papillary, 10% are nodular, and 20% are mixed. 
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GRADING 
 
 
 Grading systems are based on the degree of anaplasia of the tumor 
cells. At a consensus conference, the WHO and the ISUP decided to 
classify many of these tumors as papillary urothelial neoplasms. 
 
 A papilloma (grade 0) is a papillary lesion with a fine 
fibrovascular core covered by normal bladder mucosa. It does not have 
more than seven epithelial layers nor any abnormalities in histology. It is 
a rare, benign neoplasm and never recurs after endoscopic resection. 
 
 Well differentiated (grade I) tumors have thin fibrovascular stalk 
with thickened urothelium containing more than seven cell layers, with 
cells exhibiting only slight anaplasia and pleomorphism. There are only 
rare mitotic figures. When they are mucosally confined, these have been 
termed papillary urothelial tumors of low malignant potential (LMP). 
They often recur, and recurrences may be of higher grade and stage. 
They share the same molecular and prognostic feature as grade II 
cancers. 
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 Moderately differentiated (grade II) tumors have a wider 
fibrovascular core, a greater disturbance of the base-to-surface cellular 
maturation, and a loss of cell polarity. The nuclear-cytoplasmic ratio is 
higher. Mitotic figures are more frequent. These have been termed low-
grade urothelial carcinomas in the new WHO and ISUP classification. 
 
 Poorly differentiated (grade III) tumors, named high-grade 
urothelial carcinoma in the new WHO and ISUP classification, have 
cells that do not differentiate as they progress from the basement 
membrane to the surface. Marked nuclear pleomorphism and high 
nuclear-cytoplasmic ratio is noted. Mitotic figures are frequent. 
 The presence of metaplastic elements like squamous carcinoma 
and adenocarcinoma in urothelial carcinoma does not change the 
principal classification of the tumor as a urothelial carcinoma. 
 
 
SQUAMOUS CELL CARCINOMA (SCC) 
 
 
 These cancers occur, on the average, 10-20 years younger than 
patients with TCC. Bilharzial cancers are exophytic, nodular, fungating 
lesions that are usually well differentiated and have a relatively low 
incidence of lymph node and distant metastasis. This is due to capillary 
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and lymphatic fibrosis resulting from chronic infection. They are of 
relatively low histologic grade. Nonbilharzial SCC are usually caused by 
chronic irritation from urinary calculi, long-term indwelling catheter, 
chronic urinary infection, or bladder diverticula. Cigarette smoking is 
significantly associated with an increased risk of SCC. Male 
predominance is less striking in SCC. Its prognosis is poor as most 
patients have an advanced disease at presentation. Histologically, it 
consists characteristically of keratinized islands that contain eccentric 
aggregates of cells called squamous pearls. Cytology is of limited value 
in diagnosis. In bilharzial SCC, bone is the most common site of distant 
metastasis. 
ADENOCARCINOMA 
 
 
 Adenocarcinomas account for less than 2% of primary bladder 
cancers. They are grouped as 1. primary vesical 2. urachal 3.metastatic. 
They also occur in intestinal urinary conduits, augmentations, pouches, 
and ureterosigmoidostomies. Primary vesical adenocarcinomas can occur 
in exstrophic bladders. Signet-ring cell carcinomas characteristically 
produce linitis plastica of the bladder. They are generally of poor 
prognosis as they are advanced stage at presentation. Urachal carcinomas 
are usually adenocarcinomas , have a sharp demarcation between the 
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tumor and the adjacent bladder epithelium, with the tumor being located 
in the bladder wall beneath the normal epithelium. When they invade the 
bladder lumen, they may produce mucus in urine. Histologically they 
exhibit wider and deeper infiltration of the bladder wall than expected. 
Metastatic adenocarcinomas are from primary in rectum, stomach, 
endometrium, breast, prostate, and ovary. 
 
 
STAGING 
 
 
 The workup of a suspected bladder cancer should include a 
cytology, a cystoscopy and an upper tract study. The preference for the 
upper tract study is computed tomography (CT), as the ureter and the 
renal pelvis can be particularly visualized by the use of that technique as 
well as the relevant lymph nodes and the kidney parenchyma. Careful 
staging is important as treatment is dependent on the initial stage of the 
disease. The clinical stage of the primary tumor is determined by 
transurethral resection of the bladder tumor (TURBT). This resection 
should include a sample of the muscularis propria for appropriate 
diagnosis, particularly if the tumor appears sessile or high grade. Once 
the specimen has been removed, the base of the resected area should be 
 15
separately biopsied. Any suspicious areas in the remainder of the bladder 
should be biopsied, and a biopsy of the prostatic urethra is also done. 
 
 Patients who have documented muscularis propria –invasive 
bladder cancer require an additional set of investigations. CT scanning is 
the most commonly employed imaging modality for the staging of 
invasive bladder cancer for the evaluation of the pelvis and 
retroperitoneal lymph nodes. The correlation of CT findings with 
pathology of the cystectomy specimen is 65-80%. CT detects metastatic 
disease in regional lymph nodes in 50-85% cases. 
 
 Magnetic resonance imaging (MRI) has gained considerable 
popularity as an imaging technique for invasive bladder tumors. Failure 
to detect microscopic nodal disease with MRI is similar to that of CT. 
Understaging and overstaging remain persistent problems with both CT 
and MRI, occurring in about 30% of cases. 
 
 Preoperative bone scan is not necessary for patients with clinically 
organ confined, muscle invasive bladder cancer. For patients who have 
signs or symptoms suggestive of bone involvement, bone scan may 
provide additional information that could provide additional information 
that could change the therapeutic recommendations under consideration. 
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Suspicious bone scan results are correlated with MRI findings to 
increase diagnostic accuracy. 
 
 FDG-PET appears to be a useful modality in conjugation with 
conventional imaging studies for identifying distant sites of metastases. 
The detection of the primary tumor, local tumor recurrence, and regional 
pelvic lymph node metastases is limited due to the presence of excreted 
FDG in the urinary tract, the deficiency that is only partially overcome 
by continuous irrigation during the study.  With the advent of new 
tracers that are not really excreted, PET may play a greater role in the 
diagnosis and locoregional staging of bladder cancer. 
 
 
ANATOMY AND LYMPHATIC DRAINAGE 
 
 
 The urinary bladder is a muscular reservoir of urine, which lies in 
the anterior part of the pelvic cavity. An empty bladder is tetrahedral in 
shape and has an apex, directed forwards; a base or fundus, directed 
backwards; a neck, which is the lowest and most fixed part of the 
bladder; three surfaces, superior, and right and left inferolateral. The 
apex is connected to the umbilicus by the median umbilical ligament 
which represents the obliterated embryonic urachus. In the female, the 
base is related to the uterine cervix and to the vagina. In the male, the 
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upper part of the base is separated from the rectum by the rectovesical 
pouch and the coils of intestine; and the lower part is separated from the 
rectum by the seminal vesicles and the vasa deferentia. The triangular 
area between the two deferent ducts is separated from the rectum by the 
rectovesical fascia of Denonvilliers. The neck is the lowest and most 
fixed part of the bladder. In males, it rests on the base of the prostate 
with which its walls are continuous. In females, it is related to the pelvic 
fascia which surrounds the upper part of the urethra. The inferolateral 
surfaces of the bladder are devoid of peritoneum, and are separated from 
each other anteriorly by the anterior border, and from the superior 
surface by the lateral borders. In the males, each surface is related to the 
pubis, the puboprostatic ligaments, the retropubic fat, the levator ani and 
the obturator internus. In the females, the relations are the same, except 
that the puboprostatic ligaments are replaced by the pubovesical 
ligaments. In an empty bladder, the greater part of the mucosa shows 
irregular folds due to its loose attachment to the muscular coat. In a 
small area over the lower part of the base of the bladder, the mucosa is 
smooth due to its firm attachment to the muscular coat. This area is the 
trigone of the bladder. The internal urethral orifice is located at the apex 
of the trigone. The ureters open at the posterolateral angles of the 
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trigone. The main arterial supply of the bladder comes from the superior 
and inferior vesical arteries, branches of the anterior trunk of the internal 
iliac artery. Additional supply is derived from the obturator, inferior 
gluteal arteries; and in females, from the uterine and vaginal arteries. 
Venous drainage is into the vesical venous plexus on the inferolateral 
surfaces of the bladder. Veins from this plexus pass backwards in the 
posterior ligaments of the bladder, and drain into the internal iliac veins. 
Most of the lymphatics from the urinary bladder terminate in the external 
iliac nodes. Some anterior and lateral drainage may go through the 
obturator and internal iliac nodes, whereas portions of the bladder base 
and trigone may drain into the internal and common iliac groups. The 
common iliac nodes receive efferent vessels from the external and 
internal iliac nodes and the pelvic ureter and drain into the lateral aortic 
nodes. 
 
 
MANAGEMENT OF SUPERFICIAL AND MUSCLE INVASIVE 
BLADDER CANCERS 
 
 
 The term superficial bladder cancer refers to Ta, T1 and Tis 
lesions of any grade. The principal technique for the diagnosis and 
management of superficial bladder lesions remains endoscopic 
management, generally by cystoscopy and TURBT. After complete 
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resection, normal muscle fibers should be visible at the base. When a 
repeat TUR is performed within several days to weeks of the original 
procedure, residual tissue may be seen in as high as 40-75% of cases. In 
the evaluation of T1 tumors specifically, a repeat TUR can demonstrate 
worse prognostic findings in up to 25% of specimens. The Nd:YAG 
laser has been employed for patients with superficial bladder cancers 
with recurrent low grade lesions. Little bleeding occurs. High cost, 
absence of available tissue for pathological analysis and risk of 
perforation due to forward scatter of laser energy are the disadvantages. 
Photodynamic therapy has been studied in Tis and papillary T1 lesions 
with a response rate of 50-60%. 
 
 Intravesical therapy can serve as adjuvant treatment, as therapy for 
residual disease, or as a means of disease prophylaxis. The goal of 
intravesical therapy with chemotherapeutic agents is to decrease 
recurrence, prevent progression, and eradicate residual disease after 
TURBT. The ideal agent would be inexpensive; have minimal toxicity, 
either locally or systemically; and be administered in a single dose. BCG 
remains the most effective form of intravesical therapy for prophylaxis 
and treatment of superficial bladder cancer. BCG accumulates and 
adheres to the bladder wall. It is then internalsed and processed by 
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professional APC and tumor cells. BCG antigens are presented via MHC 
class II molecules to CD-4 T cells and via MHC class I molecules to 
CD-8 T cells. Production of chemokines such as IL-8 contributes to the 
local activation of the immune system. Activated leucocytes and 
mononuclear cells invade the bladder wall. Th1 response occurs with 
particular cytokines (IFN-y,IL-2,IL-12 and TNF-b). This cytokine 
profile promotes delayed type hypersensitivity response, cytotoxic cell 
response, macrophage activation or cellular immune inflammatory 
reaction. The Th1 cytokine profile enables recruitment and maturation of 
cytotoxic effector cells. Some of the cytokines, NK cells and BCG itself, 
may exhibit a direct cytotoxic effect on tumor cells. Mitomycin C, 
Doxorubicin, Epirubicin, Thiotepa and Valrubicin are chemotherapeutic 
agents that can be used for intravesical chemotherapy. 
 
Indications for Intravesical therapy: 
 
1. Multifocal Tis 
2. Tis with residual Tis or Ta lesion 
3. Rapid recurrence after TURBT 
4. Prophylaxis after complete TURBT for T1 lesions and high 
grade Ta lesions 
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 The role of radiation therapy in the treatment of superficial 
bladder cancer is limited and generally restricted to those individuals 
who refuse cystectomy after the failure of intravesical therapy or who are 
unsuitable for major surgery. 
 
 The use of cystectomy in the treatment of superficial bladder 
cancer must be evaluated in terms of the benefits  and limitations of 
current intravesical therapy, the morbidity of major surgery, and our 
ability to predict the potential progression of high-risk superficial disease 
in individuals. Radical cystoprostatectomy in the male patient and 
anterior pelvic exenteration in the female patient, coupled with en bloc 
pelvic lymphadenectomy , remains the standard surgical approaches to 
muscle invasive bladder carcinoma in the absence of metastatic disease. 
Despite alternatives that may appear appealing and may be appropriate 
for certain individuals, surgical removal still provides local control and 
chance for cure, to which other treatments attempt to compare 
themselves. 
 
Indications for Radical cystectomy: 
 
1. Persistent/recurrent high-risk superficial disease who failed 
intravesical therapy 
2. Muscle invasive TCC in the absence of metastasis 
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3. Multifocal T1 grade III 
4. T1 grade III with Tis 
5. Rapid recurrence after intravesical therapy especially if 
multifocal 
6. Involvement of prostatic stroma 
7. Concomittent Tis of urethra 
8. Failure of bladder preservation-chemoradiation 
9. Tumor arising in bladder diverticula 
 
 The patient’s health status is optimized prior to cystectomy. Age 
and co morbidities should not be used as absolute deterrents when 
considering radical cystectomy as therapy for a potentially lethal cancer. 
Patients are seen preoperatively by an enterostomal nurse for counseling 
and optimal stoma site marking. This is recommended regardless of 
diversion type planned in the event that an orthotopic diversion is not 
technically feasible or contraindicated. Prior to surgery, patients undergo 
a mechanical and antibiotic bowel preparation usually performed in the 
out patient setting after 1-2 days of clear liquid diet. Patients are 
routinely admitted one day prior to surgery with an estimated length of 
stay between 10 and 14 days. 
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 In a male, the prostate and seminal vesicles are removed routinely 
along with the bladder and is equivalent to anterior exenteration. 
Reasons for routine removal of the prostate include direct extension of 
the bladder cancer into the prostatic urethra, as well as prostatic ductal or 
stromal involvement. There is also a risk of secondary malignancy, 
namely, prostatic adenocarcinomas, which has been detected in up to 
40% of specimens in historical cases. 
 
 A better understanding of the anatomic relationships of the 
neurovascular bundles with respect to the prostate combined with 
improved surgical technique has led to major improvements in functional 
outcomes. Retaining potency in men following radical cystectomy is also 
technically feasible and involves careful attention to the area of the 
prostatic pedicles, where nerve bundle injury is most likely. Currently, it 
has been reported that potency is preserved in about 50% of men with 
nerve-sparing techniques and there has been no apparent compromise in 
cancer control. 
 
 Urinary reconstruction following cystectomy involves the 
reconnection of the ureters to an intestinal segment that allows for the 
drainage of urine. There are essentially three methods in which this can 
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be accomplished: an ileal conduit, a continent cutaneous reservoir, or an 
orthotopic urinary diversion. Historically, a majority of patients 
underwent an ileal conduit, an incontinent form of  urinary drainage. 
Over the past decade, however, continent urinary diversions, especially 
orthotopic bladder reconstruction, have evolved from experimental 
surgery to become a commonly performed method of urinary diversion. 
The detection of cancer in young patients, the desire to maintain a 
normal body image, and the realization that quality of life can be 
improved by maintaining near-normal function after radical surgery, and 
improved surgical techniques have all contributed to the realization that 
continent urinary diversion is an option for a significant percentage of 
patients. 
 
 Patient selection criteria include both patient factors and cancer 
factors. An absolute contraindication in a male patient is the inability to 
achieve a negative cancer margin in the proximal urethra (prostatic 
apex). Relative contraindications to orthotopic urinary diversion include 
renal insufficiency, hepatic dysfunction, and the inability to perform self-
catheterisation should the need arise. Although controversial, age alone 
is not a contraindication to orthotopic diversion and thus can be 
performed judiciously in men over 70 years of age, and even in men with 
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significant co morbidities. Prior pelvic radiation therapy is again a 
relative contraindication; however, there have been reports of successful 
orthotopic diversion in the setting of salvage cystectomy for failed 
radiation. 
 
 Orthotopic neobladder construction involves the creation of an 
internal reservoir from some segment of bowel, most commonly this is 
45 to 60cm of ileum, detubularized and fashioned in either a “ W 
configuration” (Hautmann) or “ U shaped or J shaped” (Studer). At 
Cancer Institute, a “ sperm shaped” neobladder is fashioned. While in the 
past there was a fear that orthotopic diversion would be associated with a 
significantly higher rate of complication as compared to an ileal conduit, 
recent reports suggest that in properly selected patients the early 
complication rates are similarly acceptable. 
 
 The functional results following orthotopic urinary reconstruction 
have been excellent. Daytime urinary continence rates range from 80 to 
95% with differences largely due to definition of continence, methods in 
which data are obtained, and length of follow-up. Nighttime continence 
is more problematic, with rates of 65 to 85% reported. The incidence of 
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hyper-continence or urinary retention requiring self-catheterisation is 
approximately 3 to 5%. Men should be counseled preoperatively that 
while most men are continent in the day, they may experience some 
degree of incontinence at night and a protective pad may be required. 
Overall patient satisfaction with orthotopic neobladder substitution 
remains high with >95% of patients satisfied with their choice of 
diversion. 
 
 In women, radical cystectomy for muscle invasive bladder cancer 
has historically been equivalent of an anterior exenteration. This includes 
removal of the uterus, fallopian tubes, ovaries, bladder, urethra, and a 
segment of anterior vaginal wall. This remains the gold standard. 
However, early detection combined with a desire to improve the 
functional outcomes, including sexual abilities and urinary control, has 
led surgeons to modify their techniques in selected patients, where 
preservation of disease-free urethra is possible. 
 
 Although the majority of women still undergo ileal conduit 
urinary diversion or continent cutaneous diversion, orthotopic urinary 
diversion has become increasingly viable as an option. Exclusion criteria 
for orthotopic neobladder reconstruction include tumor involving the 
bladder neck, diffuse Tis, and a positive bladder neck margin at the time 
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of radical cystectomy. In addition, females with large , palpable tumors 
along the anterior vaginal wall are not appropriate candidates. In 
properly selected patients, local recurrence rates have been extremely 
low and function outcomes have been comparable to those reported 
among males patients. 
 
 The technique and outcomes of orthotopic diversion in females 
have well been described. These technical refinements include avoidance 
of overlapping suture lines, the interposition of a vascularised omental 
pedicle, and preservation of anterior vaginal wall. In patients with non 
palpable tumors, the plane between the posterior bladder wall and the 
anterior vaginal wall can be developed while ligating the posterior-lateral 
pedicles. The plane is developed to the level of the bladder neck, and the 
anterior and posterior dissections are connected with preservation of the 
bladder neck. 
 
 In most women, the risk of gynaecologic involvement of urothelial 
malignancy is small and can usually be determined either preoperatively 
or at the time of surgery. The potential for improved functional outcomes 
and quality of life through preservation of gynaecological organs, 
particularly among young women with invasive bladder cancer, is 
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currently an area of ongoing research, and these younger women are 
more likely to be concerned about preservation of fertility and 
continuation of normal hormonal status. 
 
 In properly selected patients, functional outcomes have been 
comparable to those among male patients. Daytime continence rates 
range from 70 to 95%, with high rates of overall satisfaction. There may 
be a higher rate of urinary retention regarding intermittent 
catheterizations, and all patients undergoing diversion should receive 
preoperative counseling regarding this, as well as other possible 
complications. 
 
 Although it has long been a standard part of radical cystectomy, 
pelvic lymph node dissection has garnered more attention recently. This 
is derived in part from data demonstrated long-term disease-free survival 
among node-positive patients and benefit implied from the completeness 
of the lymph node dissection. It has been proposed that the therapeutic 
benefit of lymphadenectomy may be extended beyond the confines of 
the traditional pelvic template arguing in favour of a more extended node 
dissection. Recent studies have proposed that the actual number of nodes 
harvested may play a role in patient outcomes, and the greater the lymph 
nodes removed the better the survival. 
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 The concept of lymph node density, defined as the total number of 
positive lymph nodes divided by the total number of lymph nodes 
removed, has been reported to be an important prognostic indicator 
among patients with node-positive bladder cancer. The benefit of an 
extended dissection may be derived from both the removal of clinically 
apparent pathologic nodes and/or from undetected micrometastatic 
disease. Future studies that carefully document the overall number and 
location of lymph nodes removed (mapping) along with the number and 
location of positive nodes removed at the time of cystectomy using 
defined templates of dissection and possibly molecular staging will be 
important. 
 
 When performed as a salvage procedure following definitive 
radiation treatment (>50 Gy), a pelvic lymphadenectomy is not 
performed because of significant risk of iliac vessel and obturator nerve 
injury. 
 
 For a combined common and pelvic iliac lymphadenectomy, the 
lymph node dissection is initiated 2cm above the aortic bifurcation 
(superior limit of dissection), and the dissection extends laterally over 
the inferior vena cava to the genitofemoral nerve, representing the lateral 
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limits of dissection. Distally, the lymph node dissection extends to the 
lymph node of Cloquet medially (on Cooper’s ligament) and the 
circumflex iliac vein laterally. 
 
 The long term efficacy of radical cystectomy among patients with 
invasive bladder cancer has been demonstrated in terms of local control 
and disease-specific survival. Numerous series have demonstrated 
excellent local control and excellent 5- and 10-year survivals for patients 
with invasive bladder cancer treated with cystectomy. Long-term 
survival is best among those with organ-confined disease, and 
consistently 5-year survival >70%. 
 
 Despite significant decrease in overall mortality and morbidity 
rates associated with cystectomy, complications can occur as an 
exacerbation of the patients preexisting co morbid conditions, arising 
from the bladder removal and those arising from the use of an intestinal 
segment. The mortality rate for radical cystectomy remains 1% to 2%, 
with an overall early complication rate of about 25% to 30%. 
 
 Radical cystectomy is associated with significant blood loss  
and/or transfusion requirement, and complicating the surgical treatment 
of these patients is the significant number that have anaemia. Median 
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estimated blood loss was 600ml (range 100 to 3000ml). Increased 
estimated blood loss was related to patient age; longer operating time 
and paralytic ileus. Overall transfusion was required in 30% of patients 
with a median requirement of 2 units. These data support the need for 
continued refinement in surgical techniques designed to decrease blood 
loss, as well as for strategies designed to lower the need for blood 
transfusion during radical cystectomy. 
 
 Although the published data on neoadjuvant chemotherapy do not 
meet the standard to declare neoadjuvant chemotherapy the new standard 
of care in muscularis propria bladder cancer, the data in support of 
benefit are sufficiently compelling that patients should be informed of 
the potential benefits versus the risks of neoadjuvant therapy as part of 
the discussion leading to a decision to proceed with cystectomy. Until 
the completion of a well-designed and well-executed clinical trial(s), 
sufficiently powered to settle the question, the place of adjuvant 
chemotherapy will necessarily remain uncertain. 
 
 In certain patients, radical cystectomy may not be the best option, 
and bladder preservation strategies for the treatment of invasive cancer 
have evolved for several reasons. Advances in the treatment of other 
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malignancies such as breast and esophageal cancer, have demonstrated 
the effectiveness of this strategy. In bladder cancer, the majority of 
patients with recurrent and metastatic disease die of disease that is 
distant in location as opposed to local. In addition, despite its accepted 
standard as the treatment of choice, radical cystectomy does not 
ultimately result in a cure in a large number of patients and still 
represents a significant operative procedure with associated 
complications. Many bladder cancer patients are elderly, and although 
the number is decreasing with improvements in surgical techniques and 
perioperative care, there are patients “too ill” to undergo radical 
cystectomy. 
 
 Although this approach has its appeal it remains only an option, 
and radical cystectomy continues to be the standard treatment of choice. 
Survival data for bladder sparing approach presented in a certain light 
can first appear promising, but it is difficult to compare directly how 
patient survival rates differ between bladder-sparing regimens and initial 
radical cystectomy. This is true when a significant number of patients do 
eventually require cystectomy, which is in fact delayed by the bladder 
sparing approach. This strategy often requires a multitude of visits to 
different physicians requiring often invasive procedures to attempt to 
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monitor closely the patient’s condition and tumor status. In addition, 
bladder-sparing protocols are not in themselves inherently risk-free and 
have associated possible complications. To date, no prospective 
randomized trial has been performed comparing a multimodality 
bladder-sparing approach with radical cystectomy. 
 
 Partial cystectomy is a bladder-sparing surgical approach. This 
approach could be advocated in a limited group of patients. Those 
patients who may be reasonable candidates would include small, single 
tumors, away from the trigone without related Tis. Although bladder 
capacity may not be enough to maintain normal voiding patterns, this 
remaining bladder tissue serves as an area for recurrent disease or 
previously unrecognized disease. Localized recurrence in the form of 
new tumors or recurrent tumors occur anywhere between 15% and 75% 
of the time. This form of therapy should not be accepted as a standard 
treatment choice. 
 
 The combination of transurethral resection, radiation, and 
chemotherapy for bladder preservation has yielded better results than any 
of the monotherapies with an improved clinical complete response rate. 
Substantial improvements in local control have been reported with 
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combined modality therapy. This generally consists of TURBT for 
debulking with the goal a visibly complete tumor removal followed by 
radiation treatment with concurrent radiosensitizing chemotherapy. In 
the studies reported, the most commonly used radiosensitizing drugs 
have been cisplatin, 5-flurouracil (5-FU), and paclitaxel, used either 
singly or in various combinations. 
 
 The results of trimodality therapy for muscle-invasive bladder 
cancer have led to further studies utilizing trimodality treatment with 
improved radiation techniques and the use of newer chemotherapeutic 
agents in innovative combinations in attempts to improve on the 
complete response rate and the long-term control rate in the treatment of 
muscle-invasive bladder cancer. 
 
 The absolute contraindication for bladder preservation protocol 
treatment is hydronephrosis. The relative contraindications are presence 
of Tis, incomplete TURBT and patients not fit for cystectomy, if the 
need for the same arises. One-third of patients entering a potential 
bladder preservation protocol with trimodality therapy, will require 
cystectomy. 
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 In bladder preservation protocol, patients undergo TURBT. R0 
resection is achieved. Radiation treatment is started 2 to 6weeks after 
TURBT. 50 to 55Gy radiation is given in conventional fractions to the 
bladder and the regional lymph nodes, and a boost is given to bladder or 
tumor bearing bladder area. Concurrent chemotherapy is delivered. 
Response is evaluated during or soon after treatment. If complete 
response is achieved, no further treatment is given. If the residue is 
superficial, reTURBT is done. If gross residue is present, then patient is 
taken up for salvage cystectomy. Multifocality of primary tumor was 
associated with higher risk for local recurrence. 
 
 The quality of life in patients whose bladders have been preserved 
has been studied in various centers. 78% have compliant bladders with 
normal capacity and flow parameters. 85% have no urgency or 
occasional urgency. 25% have occasional to moderate bowel control 
symptoms. 50% have normal erectile functions. 
 
 Lifelong surveillance with cystoscopy is crucial in patients treated 
with bladder-sparing therapy. Prompt salvage therapy for superficial or 
recurrent invasive disease likely has prevented a survival disadvantage. 
The 10-year overall survival and disease-specific survival in bladder-
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sparing protocols are comparable to the results reported with 
contemporary radical cystectomy. For patients of similar clinical and 
pathological stage, one-third of patients treated on protocol with the goal 
of bladder sparing ultimately required a cystectomy. A trimodality 
approach with bladder preservation based on the initial tumor response is 
therefore safe and appropriate treatment with the majority of long-term 
survivors retaining functional bladders. 
 
 Urinary diversion is necessary in patients who undergo 
cystectomy for bladder cancer. Alternative urinary drainage may be 
either temporary or permanent. Permanent forms of urinary diversions 
can be accomplished by establishing direct continuity between the 
urinary tract and the skin or, more commonly, by interposing a segment 
of bowel between the urinary tract and skin. Nearly all segments of 
bowel have been described for use in urinary diversion, and despite 
extensive study, no single method or portion is ideal for all patients and 
clinical settings. The specific method of urinary diversion should be 
selected based on the indication for diversion, individual patient 
preference, anatomy, renal function, and overall health. 
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 Urinary diversions can be broadly categorized into those that are 
continent and those that are incontinent. Continent forms of urinary 
diversion are achieved with either a continence mechanism to an 
abdominal stoma or with an orthotopic bladder substitute relying on 
intrinsic continence after anastomosis to the native urethra. Noncontinent 
types of urinary diversion generally act simply as a conduit through 
which the urine exits the body, thus requiring an external appliance to 
collect the urine. Although continence after reconstruction permits 
freedom from an external collection bag, these operations may be 
technically more difficult and associated with higher complication rates. 
Continent diversion, however, can benefit the patient with regard to 
psychologic aspects, with preserved self-image and sexuality. Overall, 
patient report a high level of satisfaction with both continent and 
noncontinent forms of urinary diversion. 
 
 Seiffert first described an ureteroileocutaneous diversion in 1935. 
The procedure was subsequently popularized by Bricker and remains the 
most commonly used method of noncontinent urinary diversion. Patient 
selection, proper stoma location, and careful technique in creating a 
well-vascularized stoma are all important to the success of the procedure. 
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 An ileal conduit may be contraindicated in patients with a history 
of regional enteritis or extensive pelvic irradiation. In these situations, a 
colon conduit may be preferable. The typical stoma is located in the right 
lower quadrant. The usual site is located along a line from the anterior 
superior iliac spine and the umbilicus, at the lateral edge of the rectus 
abdomens muscle. It is important to bring the stoma through the rectus 
muscle to help prevent the development of a parastomal hernia. In order 
to minimize the absorptive surface of the bowel in contact with urine, the 
ileal segment should be as short as feasible. Reabsorption of urinary 
constituents does not cause a significant problem in patients with normal 
renal function but metabolic abnormalities may develop in those with 
renal insufficiency. 
 
 Jejunal conduit urinary diversion should be reserved for patients in 
whom other, more suitable options are unavailable. These include those 
with prior pelvic irradiation, inflammatory bowel disease, or loss of the 
middle and distal ureters. Electrolyte disturbances are more common in 
those with urinary conduits using the jejunum. 
 
 The colonic conduit was popularized by Turner-Warwick in 1960. 
Urinary conduits constructed from large intestine have several potential 
advantages when compared to those made using small intestine. First, 
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non-refluxing ureteral anastomoses are possible using either a short 
tunnel through the teniae coli or the ileocaecal valve. Second, stomal 
stenosis is less common due to the larger lumen of the colon. Third, a 
suitable segment of the colon outside of the field of previous abdominal 
or pelvic irradiation is usually available. When use of the colon is 
anticipated, a preoperative contrast imaging study of the large bowel or 
colonoscopy should be considered. 
 
 The ileocecal conduit was first described by Zinman and Libertino 
in 1975. This method utilizes the ileocaecal valve as an antireflux 
mechanism for the ureters. Other advantages of this portion of the bowel 
include the constant and abundant blood supply and location in the right 
lower quadrant, facilitating stoma formation. The ileocecal segment is 
rarely affected by generalized bowel disorders, such as diverticulitis. 
 
 The transverse colon conduit is well suited for patients who have 
received extensive pelvic irradiation, making the small bowel 
suboptimal, or situations where the distal ureters are damaged or absent. 
In situations of inadequate ureteral length, the transverse colon segment 
can be directly anastomosed to both renal pelvis. The sigmoid colon 
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conduit should be avoided in patients with a history of pelvic irradiation. 
A sigmoid colon conduit is also questionable in those undergoing 
cystectomy because the vascular supply to the rectum may be 
compromised if the internal pudendal artery is ligated. 
 
 Continent cutaneous (non-orthotopic) techniques can be divided 
into two major categories: (1) urinary diversion into rectosigmoid and 
(2) continent urinary pouches requiring clean intermittent 
catheterization. 
 
 The rectal bladder urinary diversions allow excretion of urine by 
means of evacuation. Ureterosigmoidostomy can be regarded as the 
original continent diversion with reports of this procedure dating as far 
back as the 1850s. the complications are secondary malignancy, 
hyperchloremic acidosis, hypokalemia with nephropathy, and 
pyelonephritis. This procedure offers a simple form of continent urinary 
diversion when compared with the newer techniques requiring complex 
refashioning of bowel segments. Currently this procedure is reserved 
only for those individuals of advanced age where adverse long-term 
sequalae are less important. 
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 Numerous operative techniques have been developed for continent 
catheterizable urinary diversions. To perform clean intermittent 
catheterization, it is paramount that one has good hand-eye coordination. 
The choice of where to place the catheterizable stoma is based on the 
preference of the surgeon. The two most common sites are at the 
umbilicus and in the lower quadrant of the abdomen, through the rectus 
bulge and below the “bikini” line. 
 
 Perhaps the single most demanding technical aspect during 
creation of a continent urinary diversion is the construction of the 
continence mechanism. Four surgical techniques have been incorporated 
to create a reliable, catheterizable continence mechanism: (1) 
appendiceal (Mitrofanoff type); (2) pseudoappendiceal tubes fashioned 
from ileum or right colon; (3) intussusepted nipple valve or flap valve, 
which avoids the need for intusseseption; (4) the hydraulic valve. 
 
 In 1982, Kock et al. reported the first 12 cases on their continent 
ileocecal reservoir, stimulating world-wide interest in continent urinary 
diversion procedures. However, the initial enthusiasm with this 
technique is tempered by a complication rate requiring additional surgery 
in half of patients, primarily for malfunction of  the efferent valve. Since 
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then, the Kock pouch has undergone several modifications. The T-pouch 
was devised as a novel continence mechanism by the group at the 
University of Southern California. It was created entirely from ileum. In 
1986, Thuroff et al. presented initial results with a cecoileal reservoir 
(Mainz I pouch) a sutured ileoileal intusseseption valve served as the 
continence mechanism in the first series of patients. The introduction of 
the more reliable appendiceal continence mechanism has greatly 
increased the acceptance of the Mainz I procedure. The preferred stoma 
site by the Mainz group is the umbilicus. 
 
 Several right colon pouches using the valve technology have been 
described- Indiana pouch, UCLA pouch, Duke pouch, LeBag pouch, 
Florida pouch, and the Penn pouch. One of the first continent cutaneous 
pouches to gain wide acceptance in the urologic community was the 
Indiana pouch developed in 1985 by Rowland et al. the major 
contribution was the creation of a reliable continence mechanism. The 
Penn pouch is an ileocecal pouch, described by Duckett and Snyder in 
1986. It was the first continent diversion employing the Mitrofanoff 
principle, wherein the appendix served as the continence mechanism. 
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 Advantages of using the gastric pouch as a urinary reservoir 
include diminished electrolyte reabsorption, inherent barrier to 
absorption of ammonium, absence of hyperchloremic acidosis, and 
reduced bacterial colonization in the acidic environment. Situations 
favoring consideration of the gastric urinary diversion include extensive 
irradiation of the lower bowel, preexisting metabolic acidosis or renal 
insufficiency, and patients in whom shortening the small bowel could 
result in malabsorption. The construction of reservoirs entirely from 
stomach has not seen widespread acceptance. Rather, use of stomach 
segments has been limited to bladder augmentation or as part of a 
composite reservoir. 
 
 Improvement in cosmetic results and documented increases in 
quality-of-life outcomes will encourage more surgeons to perform 
orthotopic bladder substitutions. Appropriate attention is given to 
preoperative patient selection, specific intraoperative surgical details, 
and most importantly, meticulous postoperative patient follow up. 
Advances in surgical techniques together with increased understanding 
of the pelvic anatomy and natural history of TCC, general physiology, 
and female continence mechanism have resulted in improved functional 
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outcomes emulating those in men. The ileal low pressure bladder 
substitute with an afferent tubular segment is easily constructed and has 
documented good long-term functional results in both sexes. 
 
 A successful outcome of a bladder substitution requires the 
cooperation of the patient and the willingness to comply with long-term 
follow up. The commonest biochemical abnormalities detected following 
bladder substitution are metabolic acidosis and electrolyte abnormalities. 
Adequate preoperative renal function is required to limit such 
complications. Identification of incontinence prior to surgery, especially 
in females is essential. Urge incontinence is likely to be treated by 
cystectomy; however, stress incontinence, which is due to inadequate 
sphincter function, needs to be further evaluated by urodynamic 
assessment with an urethral pressure profile. Patients with a grade I 
genuine stress incontinence, a normal functional urethral length, a 
hypermobile bladder neck and absence of a large cystocele could benefit 
from a bladder substitute. However, if there is documented evidence for 
a shortened functional urethral length or intrinsic sphincter deficiency, 
incontinence following an orthotopic bladder substitute can be expected. 
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 To achieve good functional result, the bladder substitution has to 
have a good capacity, a low-pressure system made of detubularised 
bowel segments with minimal outlet resistance and preserved sphincter 
function. Preservation of the autonomic nerves to the sphincter and 
urogenital diaphragm is controversial, but it is felt that it should be 
attempted on the nontumor bearing side (in bladder cancer) as it will 
increase the chance of potency in the male and aid urinary incontinence 
in both sexes. Ileal segment is used to create the bladder substitute. A 54- 
to 56-cm segment of ileum is isolated 25cm proximal to the ileocecal 
valve. For reservoir construction, a sperm-shaped bladder substitute is 
fashioned. The in-hospital postoperative period should be utilized for 
patient education and to help adjust to their bladder substitute. Metabolic 
acidosis is the commonest biochemical abnormality following a bladder 
substitution. In virtually all patients, short-term treatment with sodium 
bicarbonate 2 to 6gm/day will be needed, which is ceased within 3 
months time, as the mucosa of the reservoir becomes more resilient to 
electrolyte and fluid exchange. Diurnal continence of up to 83% in 
women and 90% in men with nocturnal rates over 80% at 12 months 
should be achieved in both sexes. Incontinence rates tend to increase in 
the absence of a nerve-sparing cystectomy, in the older patients and 5 
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years following a cystectomy. The incontinence is generally minimal and 
not debilitating with normal transurethral voiding achievable in up to 
97% of patients. 
 
 Recommended follow up is every 3 months for the first 3 years, 
then 6 monthly for the next 2 years, and the annually. Clinical 
examination, urine cultures, body weight and blood gas analysis are 
recommended at each visit. Chest x-ray and urethral/ureteric wash 
cytology is done 6 monthly for first 2 years, and then annually. CT scan 
of the abdomen/pelvis is done annually. Symptomatic cases will require 
a bone scan for evaluation. 
 
 The proportion of patients developing upper tract TCC after the 
diagnosis and treatment of superficial bladder cancer has classically been 
reported as 0.002%. Most occurrences present within the first 5 years. 
Lifelong observation of upper tracts with routine intravenous urograms 
on a yearly basis or at the detection of positive urinary cytology is 
required for high risk superficial disease. There are few data to support 
for such intense follow-up in low-risk patients, but evaluation of the 
upper tracts on a 3- to 4- year schedule is reasonable. 
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Recurrence pattern versus grade: 
 
 GRADE 1 GRADE II GRADE III 
Loco-regional - 1 5 
Distant - 1 4 
 
 
 
Recurrence pattern versus stage: 
 
 STAGE I II III IV 
Loco-regional - 1 2 3 
Distant - 3 1 1 
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Recurrence pattern versus Extent of lymphadenectomy: 
 
 < 10 LN YIELD 11-20 21-30 31-40 
Loco-regional 2 3 1 - 
Distant 1 2 1 1 
 
 
Recurrence pattern versus Pathological nodal status: 
 
 pN0 pN1 pN2 pN3 
Loco-regional 2 3 - 1 
Distant 4 - 1 - 
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RESULTS 
 
 
 
 
 The study includes all patients who underwent radical cystectomy 
for bladder cancer from January 2001 to March 2007. There were 38 
cases in the study. One case was excluded from the study as the final 
histopathology revealed a leiomyoma of the bladder. Hence there were 
37 cases in the study. 
 
 The male to female ratio in the study was 5.2:1. The youngest in 
the study population was 21 year old and the oldest in the study 
population was 80 year old man. The mean age who underwent surgery 
was 58 years and the median age was 60 years. The most common 
presenting complaint was painless haematuria. The mean duration of 
presenting symptom was 3 months. 13 of 37 patients had co morbid 
illnesses like diabetes mellitus, hypertension, and bronchial asthma. 
There was no significant family history of cancer or cancer syndromes. 
 Of the 37 patients included in the study, 16 of them were smokers. All 
the smokers were men. The mean duration of smoking was 24 years 
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 Urine cytology was positive in 11 cases. It was associated with 
grade III disease in 9 cases, grade II in one case and grade I in one case. 
The sensitivity of urine cytology in this study was 30%. At 
cystoscopy,20 cases were found to be solitary lesions,&17 of them were 
multiple. Ultrasound of the pelvis correlated well with the cystoscopy 
findings. CT scan of the abdomen also correlated well with the 
cystoscopy findings. Ultrasound and CT scan failed to detect gross 
pelvic lymph node enlargement in one case, frozen section of the same at 
surgery was positive for metastatic disease. Chest x-ray did not reveal 
any abnormality in any of the cases. Bone scan was not done as a routine 
staging investigation, unless there was any symptomatic bone pain or 
raised serum alkaline phosphatase that warranted a confirmation. 
Suspicious uptakes at bone scan were evaluated using MRI scan, and 
metastatic diseases were eliminated from the study. 
 
 37 patients underwent radical cystectomy. Ileal conduit was 
fashioned in 27 cases. Transverse colon was used to fashion conduit in 2 
cases. Orthotopic neobladder was created in 8 patients, which included 5 
males and 3 females. The most common indication for radical 
cystectomy in the study group was muscle invasive-grade III bladder 
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cancer. Two cases of radical cystectomy was for extensive and 
inaccessible growths, for whom TURBT was incomplete. The pathologic 
status of both these cases were pT3. Three cases underwent salvage 
cystectomy after definitive radiation. One of them had recurrence after 
radiotherapy and the other two were bladder cripple after radiation. Two 
of them had transverse colon as conduit. One patient underwent radical 
cystectomy after due to recurrence after chemoradiation (60 Gy radiation 
along with 6 cycles cisplatin). The pathological staging after surgery was 
pT2 and the patient is disease-free at 6 years. Three patients underwent 
radical cystectomy for recurrence during or immediately after 
intravesical BCG. A total of six patients had received intravesical BCG 
before radical cystectomy. 
 
 The most common final histology was transitional cell carcinoma 
(TCC) in 84% cases. Other histological variants in the group were 
squamous cell carcinoma (SCC), adenocarcinoma and poorly 
differentiated carcinoma. 70% of the cases belonged to high grade 
variety. Pathological T status was pT3 in 13 cases, pT2 in 18 cases and 
pT1 in 6 cases. Pelvic lymph node dissection was done in all cases. 
Pathological N status was pN1 in 6 cases. They were classified as stage 
IV as per AJCC classification. One patient had gross pelvic 
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lymphadenopathy at surgery, frozen section of which revealed metastatic 
deposits. It was decided to proceed with surgery, and the patient failed in 
6 months time with nodal recurrence in the pelvis. 
 
 Major postoperative morbidity was seen in 8 cases (21.6%). Most 
common complication was leak. The incidence of leak was 8%. The 
other major complications encountered were acute renal failure, vesico-
vaginal fistula, deep vein thrombosis, and urinary tract infection. Long 
term follow up revealed one instance of adhesive intestinal obstruction 
and incisional hernia repair. 
 
 Adjuvant chemotherapy was delivered to one patient whose 
pathological disease status was pT3N0M0 grade III. 6 cycles of cisplatin 
and gemcitabine was given. The patient had a disease-free survival of 23 
months. Recurrence was locoregional. It is the Institute policy not to 
deliver neoadjuvant or adjuvant chemotherapy for resectable bladder 
cancer as of now. 
 
 Final pathological stage was stage I 13.5%, stage II 43.2%, stage 
III 27% and stage IV 16.2%. Surgical staging has upstaged the clinical 
stage in 43.2%.  
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 All patients were followed up to October 2007 and the pattern of 
recurrence was studied. 70% of patients did not have any recurrence. 
54% had recurrence in the pelvis (locoregional). 45% had failed at 
distant sites. Pelvic failure was in the form of nodal recurrence. The 
different sites of distant failure were bone (most common), liver, and 
CNS. Palliative radiation to pelvic nodal recurrence and spinal 
metastasis was given in selected cases. 
 
 Of the recurrences, 82% had grade III disease at presentation and 
18% had grade II disease, signifying grade as a prognostic factor and that 
high grade disease was associated with poor prognosis and decreased 
disease-free survival. None of the stage I disease recurred at follow up. 
36% of the recurrence belonged to stage II and 27% of the recurrence 
belonged to stage III.  
 
 When the nodal yield was 31-40, there was no instance of loco-
regional failure. 16% of loco-regional failure had initial nodal yield 
between 21-30, 50% had nodal yield between 11-20 and 33% had nodal 
yield less than 10. This implies that extensive nodal dissection can 
decrease the loco-regional recurrence. When 1 lymph node has disease, 
the study revealed failure loco-regional. In the study, one case had 3 
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positive lymph nodes, and at follow up, the patient had distant failure. 
One case had gross pelvic lymph nodes at surgery, which were not 
detected preoperatively. Frozen section of the lymph nodes were positive 
for metastatic deposits. It was decided to proceed with radical 
cystectomy, and upon follow up, the patient failed in 6 months due to 
loco regional failure due to recurrent pelvic lymph nodes. 
 
 Of the recurrences, 54% were nonsmokers and 46% were 
smokers. 72% of the recurrences belonged to the 46-60 year age-group. 
All the recurrences occurred in the 41-80 year age group. 
 
 All patients who had noncontinent diversion in the form of ileal or 
tranverse colon conduit had high level of satisfaction. There was one 
instance of parastomal hernia. 8 patients underwent continent urinary 
diversion in the form of orthotopic neobladder. It included 5 males and 3 
females. The oldest patient to have orthotopic neobladder in this series 
was 65 years. Of these patients, two had incontinence, which included 
one female. 7 patients had daytime continence of more than 3 hours. 
Overall, patients with orthotopic neobladder enjoyed a good quality of 
life. 
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 Cumulative disease-free survival at 70 months in the study was 
52%. At 50 months, the disease-free survival for stage I disease and 
stage II disease was 100% and 72% respectively. At 36 months, the 
disease-free survival for stage III disease was 74%. Event-free survival 
at 36 months for stage IV disease was 40% and was zero at 40 months. 
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DISCUSSION 
 
 
 
 
 In India, the crude incidence rate of bladder cancer in males and 
females is 2.4 and 0.7/100,000 population respectively. In the world, the 
crude incidence rate of bladder cancer is 25.4 and 8.54/100,000 
population respectively. In the Madras metropolitan tumor registry, the 
crude incidence rate of bladder cancer is 2.1 and 0.8/100,000 population 
respectively. 
 
 The age distribution in the study ranged from 21 years to 80 years. 
Radical cystectomy can be performed safely, and old age is not a 
contraindication to this procedure. Co morbid conditions have to be 
optimized before the surgery. 
 
 No relation to family history of cancer or cancer syndromes were 
noted in the study. The male to female ratio of bladder cancer in this 
study was 5.2:1. In literature, bladder cancer is more than 2.5 times more 
common in men than in women. 
 60
 Urine cytology is reported to have sensitivity of 60% in high grade 
lesions and 25% in low grade lesions. In this study, urine cytology had 
an overall sensitivity of  30%. Cystoscopy, USG abdomen and CT scan 
abdomen were done routinely in all cases as part of the evaluation and 
metastatic workup. Bone scan was reserved for symptomatic cases of 
bone pain or in situations of raised biochemical parameters. All patients 
underwent an initial TURBT with deep muscle biopsy. Muscle invasive 
bladder cancer were taken up for radical cystectomy. Other indications 
were incomplete or extensive disease at TURBT, recurrence after 
radiation/chemoradiation and intravesical BCG. At present there is no 
policy to deliver neoadjuvant or adjuvant chemotherapy for bladder 
cancer undergoing radical cystectomy. Noncontinent ileal or transverse 
colon conduit; or continent orthotopic neobladder reconstruction was 
fashioned. Overall complication rate in this study was 21.6%. There was 
no operative mortality. Operative mortality for radical cystectomy has 
been shown to be between 1% and 3% in most modern series. The 
overall complication rate after radical cystectomy and urinary diversion 
in these series may be as high as 25% to 35%. 
 
 The most common histology was TCC in 84%. 70% of the bladder 
cancers in this study comprised of high grade lesions. Stage I comprised 
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13.5% of cases, stage II 43.2%, stage III 27% and stage IV 16.2%. 
Surgery has upstaged the clinical stage in 43.2% cases. All patients were 
followed up to October 2007 and the pattern of recurrence was studied. 
70% of patients did not have any recurrence. 54% had recurrence in the 
pelvis (loco-regional). 45% had failed at distant sites. Pelvic failure was 
in the form of nodal recurrence. The different sites of distant failure were 
bone (most common), liver, and the CNS. In reported series, the 
common sites of distant metastasis were liver (38%), lung (36%), bone 
(27%) and adrenals (21%). It is estimated that, almost 50% of muscle 
invasive bladder cancer already have occult distant metastases. 
 
 The incidence of loco-regional recurrence in node positive disease 
after surgery, in this study was 50% and in node negative study, it was 
9.6%. In modern series, the loco-regional recurrence in node positive 
disease after surgery was 20%, and the same in node negative disease 
was 15%. 
 
 Of the recurrences, 82% had grade III disease at presentation and 
18% had grade II disease, signifying grade as a prognostic factor and that 
high grade disease was associated with poor prognosis and decreased 
disease-free survival. When the nodal yield was 31-40, there was no 
instance of loco-regional failure. 16% of loco-regional failure had initial 
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nodal yield between 21-30, 50% had nodal yield between 11-20 and 33% 
had nodal yield less than 10. This implies that extensive nodal dissection 
can decrease the loco-regional recurrence. Leissner et al. in his series 
showed patients with and without local recurrence showed no significant 
difference in the total number of lymph nodes dissected. 
 
 In this study, the disease-free survival for pN1 was 13.3 months 
and for pN2 was 7 months. Mills et al. in his study did not find any 
difference in disease-free survival and overall survival between patients 
who had pN1 and pN2 disease. By contrast, Vieweg et al. in his series of 
bladder confined primary tumors, there was no difference in survival 
between pN0 and pN1, but pN2 fared less well. In the presence of pN3 
disease at surgery, disease-free survival was 6 months in the study. 
Similar series report zero disease-free survival at 18 months. With N3 
disease detected preoperatively or preoperatively, radical cystectomy 
was not found to be worthwhile. 
 
 Level of satisfaction was found to be high among noncontinent 
diversion and continent orthotopic bladder substitute in the study. The 
incidence of incontinence was low and daytime continence was 3 hours. 
The result was found to be comparable in other studies. 
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CONCLUSION 
 
 
 
 
 The incidence of bladder cancer is low in India and at the Madras 
Metropolitan Tumor Registry. Radical cystectomy, performed for 
muscle-invasive bladder cancer has acceptable morbidity, and level of 
satisfaction with urinary diversion is satisfactory. Pathological stage of 
the disease and grade of the tumor has a bearing on the recurrence of the 
disease. Extent of lymph node dissection and pathological nodal status 
can prognosticate local recurrence. Extended disease free survival is 
possible in stage I and stage II disease, and after extensive lymph nodal 
dissection. High loco-regional failure was observed for N3 disease after 
surgery, which questions the role of surgery in such a scenario. 
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PROFORMA 
 
 
 
 
Index No. 
 
Age/Sex: 
Presenting complaint- 
Duration – 
 
Co morbid illness- 
Family History- 
Smoking- 
 
Physical Examination- 
Urine cytology- 
Cystoscopy- 
USG Abdomen- 
CT Scan Abdomen- 
Bone scan- 
Chest x-ray- 
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TURBT- 
Intravesical BCG- 
Radiation- 
Chemoradiation- 
 
Indication for Radical cystectomy- 
Date of surgery- 
Type of surgery- 
Type of urinary diversion and conduit- 
Complications- 
 
HPE 
Type of histology- 
Grade- 
Urinary bladder- 
Ureter- 
Urethra- 
Seminal vesicle- 
Prostate- 
Lymph node status: Pelvic-             Para aortic- 
Pathological stage- 
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Adjuvant chemotherapy- 
Follow up 
Recurrence: Date- 
Loco-regional- 
Distant- 
Management of recurrence- 
 
Date of last follow up- 
Condition- 
Quality of life- 
